Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Review the latest news and information on the Coronavirus Pandemic.
read more
Review the latest news and information on the Coronavirus Pandemic.
read more
Review the latest news and information on the Coronavirus Pandemic.
read more
Review the latest news and information on the Coronavirus Pandemic.
read more
Review the latest news and information on the Coronavirus Pandemic.
read more
Review the latest news and information on the Coronavirus Pandemic.
read more
Review the latest news and information on the Coronavirus Pandemic.
read more
Review the latest news and information on the Coronavirus Pandemic.
read more
Review the latest news and information on the Coronavirus Pandemic.
read more
Review the latest news and information on the Coronavirus Pandemic.
read more
Review the latest news and information on the Coronavirus Pandemic.
read more
Review the latest news and information on the Coronavirus Pandemic.
read more
Tolmar announced plans to expand manufacturing capacity for its portfolio of products.
read more
Wednesday, January 26, 2022
Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading global provider of bio-pharmaceutical contract development and manufacturing services, is pleased to announce that Tony O’Neill has joined Aji Bio-Pharma as Vice President of Compliance, US ...
read more
BioPlan Associates’ 12th Annual Report and Survey of BioManufacturing, the industry's definitive, quantitative analysis has been released, including 12 years of biopharma trends analysis and review of current opportunities.
read more